Curis (NASDAQ:CRIS) Rating Increased to Hold at Zacks Research

Curis (NASDAQ:CRIS) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Monday, April 20th. Wall Street Zen raised Curis to a “hold” rating in a research note on Saturday, March 28th. Finally, HC Wainwright restated a “buy” rating and set a $340.00 target price on shares of Curis in a report on Friday, March 20th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $340.00.

Curis Stock Performance

CRIS opened at $4.65 on Monday. The firm’s fifty day moving average is $8.67 and its two-hundred day moving average is $14.10. The firm has a market cap of $9.07 million, a PE ratio of -0.20 and a beta of 3.08. Curis has a twelve month low of $3.61 and a twelve month high of $39.00.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). Equities analysts forecast that Curis will post -25.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in shares of Curis by 52.2% during the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 125,823 shares in the last quarter. Focused Wealth Management Inc boosted its holdings in Curis by 83.4% during the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 49,900 shares during the last quarter. XTX Topco Ltd acquired a new position in Curis during the fourth quarter worth $26,000. Squarepoint Ops LLC grew its position in Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 10,586 shares in the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.